Table 1.
The clinical characteristics of the GEO and TCGA datasets.
| Characteristics | Training cohort (GSE10846) | TCGA DLBC | Validation cohort (GSE87371) |
|---|---|---|---|
| Sample size | 305 | 48 | 221 |
| Age, years mean (SD) | 60.43 (15.21) | 56.27 (13.80) | 56.71 (16.08) |
| Gender | |||
| Female | 134 | 26 | 105 |
| Male | 171 | 22 | 116 |
| Stage | |||
| 1 | 50 | 8 | 29 |
| 2 | 94 | 17 | 42 |
| 3 | 68 | 5 | 35 |
| 4 | 93 | 12 | 115 |
| unknow | – | 6 | – |
| ≥2 Extranodal sites | 23 | – | – |
| ECOG PS>1 | 75 | – | – |
| LDH>ULN | 146 | – | – |
| Cell of origin | |||
| GCB | 133 | – | 84 |
| Non-GCB | 172 | – | 137 |
| Overall survival | |||
| Time, years mean (SD) | 3.36 (3.04) | 3.69 (3.98) | 2.92 (1.47) |
| Death | 122 | 9 | 53 |
TCGA, The Cancer Genome Atlas; ECOG PS, The Eastern Cooperative Oncology Group performance score; ULN, upper limit of normal; GCB, germinal center B-cell-like subtype.